329 related articles for article (PubMed ID: 27053454)
21. [Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].
Mascia S; Garofalo C; Donnarumma G; Di Pietro R; Liberti ME; Pacilio M; Sagliocca A; Zamboli P; Minutolo R; Conte G; De Nicola L
G Ital Nefrol; 2010; 27(6):616-28. PubMed ID: 21132644
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
Heerspink HJ
Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
[TBL] [Abstract][Full Text] [Related]
23. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
24. Cardiorenal Syndrome Revisited.
Zannad F; Rossignol P
Circulation; 2018 Aug; 138(9):929-944. PubMed ID: 30354446
[TBL] [Abstract][Full Text] [Related]
25. Heart failure in patients with kidney disease.
Tuegel C; Bansal N
Heart; 2017 Dec; 103(23):1848-1853. PubMed ID: 28716974
[TBL] [Abstract][Full Text] [Related]
26. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
Sarafidis PA; Ruilope LM
Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
[TBL] [Abstract][Full Text] [Related]
27. Dual renin-angiotensin system blockade for nephroprotection.
Ruggenenti P
Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
[TBL] [Abstract][Full Text] [Related]
28. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
29. Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.
Alexandrou ME; Theodorakopoulou MP; Kanbay M; Sarafidis PA
J Hum Hypertens; 2022 Aug; 36(8):695-704. PubMed ID: 34980878
[TBL] [Abstract][Full Text] [Related]
30. Response to Sexton: Inhibiting the renin-angiotensin-aldosterone system in patients with heart failure and renal dysfunction: common sense or nonsense?
Butler J; Givertz MM
Circ Heart Fail; 2014 May; 7(3):537-40. PubMed ID: 24847130
[No Abstract] [Full Text] [Related]
31. N-acteyl-ß-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure.
Jungbauer CG; Uecer E; Stadler S; Birner C; Buchner S; Maier LS; Luchner A
Nephrology (Carlton); 2016 Jun; 21(6):490-8. PubMed ID: 26422793
[TBL] [Abstract][Full Text] [Related]
32. Renal Response in Patients with Chronic Kidney Disease Predicts Outcome Following Cardiac Resynchronization Therapy.
Singal G; Upadhyay GA; Borgquist R; Friedman DJ; Chatterjee NA; Kandala J; Park MY; Orencole M; Dec GW; Picard MH; Singh JP; Mela T
Pacing Clin Electrophysiol; 2015 Oct; 38(10):1192-200. PubMed ID: 26179289
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic management of chronic reno-cardiac syndrome.
Hawwa N; Schreiber MJ; Tang WH
Curr Heart Fail Rep; 2013 Mar; 10(1):54-62. PubMed ID: 23143732
[TBL] [Abstract][Full Text] [Related]
34. Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially.
Palazzuoli A; Ronco C
Heart Fail Rev; 2011 Nov; 16(6):503-8. PubMed ID: 21822604
[TBL] [Abstract][Full Text] [Related]
35. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails.
Rutkowski B; Tylicki L
J Ren Nutr; 2015 Mar; 25(2):194-200. PubMed ID: 25576239
[TBL] [Abstract][Full Text] [Related]
36. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
37. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?
Yildirim T; Arici M; Piskinpasa S; Aybal-Kutlugun A; Yilmaz R; Altun B; Erdem Y; Turgan C
Ren Fail; 2012; 34(9):1095-9. PubMed ID: 22950572
[TBL] [Abstract][Full Text] [Related]
38. Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.
Wu PC; Wu CJ; Lin CJ; Pan CF; Chen CY; Huang TM; Wu CH; Lin SL; Chen YM; Chen L; Wu VC; ;
Clin Pharmacol Ther; 2015 Oct; 98(4):442-9. PubMed ID: 26082272
[TBL] [Abstract][Full Text] [Related]
39. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
Dattolo PC; Gallo P; Michelassi S; Paudice N; Cannavò R; Romoli E; Fani F; Tsalouchos A; Mehmetaj A; Ferro G; Sisca S; Pizzarelli F
J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
